By Route of Administration

The Pet Cancer Therapeutics market participants in global diesel engine and gas engine market include AdvaVet, Advaxis Inc., Amgen Inc., Aratana Therapeutics, Inc., Boehringer Ingelheim International GmbH, CanFel Therapeutics, ELIAS Animal Health, Fetch Pharma, Genentech, Innogenics, Karyopharm Therapeutics, Kindred Biosciences, Morphogenesis, Inc., NIPPON ZENYAKU KOGYO CO., LTD., Oasmia Pharmaceutical AB, PetLife Pharmaceuticals, Inc., Pharmaust., Phibro Animal Health Corporation, Regeneus Ltd, Rhizen Pharmaceuticals S.A., Torigen Pharmaceutical Inc., Vaccibody, VetDC, Virbac., Zoetis Services LLC amongst others.

The report provides both, qualitative and quantitative research of global pet cancer therapeutics market, as well as provides worthy insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in global diesel engine and gas engine market and detailed insights on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their headquarter, competitors, product/service type, application and specification, pricing, and gross margin.

Spotlight Innovation, Inc., announced that it has formed a subsidiary named, CDT Veterinary Therapeutics, Inc., to develop cancer therapeutics for the veterinary market. The company is a third subsidiary of Spotlight Innovation's along with Memcine Pharmaceuticals and Celtic Biotech. The company commercialized the production of Crotalin which is considered an effective cancer therapeutic in companion animals. According to the American Veterinary Medical Association (AAPA), veterinary care costs were approximately US$15.04 billion in the United States for the year 2014. Due to increasing costs, the North American Pet Health Insurance Association duly reported the increased companion animal healthcare insurance policies since 2009. Increasing number of such policies since then and addition of the same in the year 2013, has estimated the North America market size to be US$ 601.43 million in in 2014.

Pharmaceutical companies investing in veterinary medicine have introduced a robust pipeline of drug for the treatment of highly prevalent conditions in pets such as lymphoma and melanoma. In January 2018, Aratana Therapeutics announced approval of its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), from United States Department of Agriculture (USDA) Center. Private and government organizations such as Veterinary Cancer Society, Petco Foundation and Animal Cancer foundation are also working together with pharmaceutical companies to formulate novel drug for pet cancer therapeutics which will positively impact the industry growth.

Rising prevalence of cancer among the cats and dogs is expected to propel the overall industry growth. The Veterinary Cancer Society reported that cancer is the leading cause of death for 47.5% of the dogs who are aged over ten and 32% of the cats. The most common cancer type among the dogs are different forms of lymphoma, showing enlargement of external lymph nodes. Early detection and adequate treatment are the best way to manage cancer in pets. Most prevalent types of cancer occurs in skin, mammary gland, head & neck, testicles, abdominal cancer and bone. Cancer treatment types include surgery, chemotherapy, stereotactic radiation, conventional radiation therapy, palliative care, immunotherapy, cryotherapy and radioactive iodine I-131. Increasing investment for research and development for new diagnostic methods and treatments for cancer management will drive the growth of pet cancer therapeutics market.

1. Introduction

1.1. Market Scope

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Country-Wise Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Pet Cancer Therapeutics Market

6. Market Synopsis: Pet Cancer Therapeutics Market

7. Pet Cancer Therapeutics Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Pet Cancer Therapeutics Market

7.4. Market Determinants Radar Chart

7.5. Porter’s Five Force Analysis

7.6. Pricing Analysis, By Region (2017 and 2018)

7.6.1. North America

7.6.1.1. U.S

7.6.1.2. Canada

7.6.1.3. Mexico

7.6.2. Europe

7.6.2.1. France

7.6.2.2. The UK

7.6.2.3. Spain

7.6.2.4. Germany

7.6.2.5. Italy

7.6.2.6. Denmark

7.6.2.7. Finland

7.6.2.8. Iceland

7.6.2.9. Norway

7.6.2.10. Sweden

7.6.2.11. Russia

7.6.2.12. Belgium

7.6.2.13. The Netherlands

7.6.2.14. Luxembourg

7.6.3. Asia Pacific

7.6.3.1. China

7.6.3.2. Japan

7.6.3.3. India

7.6.3.4. New Zealand

7.6.3.5. Malaysia

7.6.3.6. Taiwan

7.6.3.7. Russia

7.6.3.8. Singapore

7.6.3.9. Hong Kong

7.6.3.10. Australia

7.6.3.11. Southeast Asia

7.6.4. Middle East and Africa

7.6.4.1. GCC Countries

7.6.4.2. UAE

7.6.4.3. Saudi Arabia

7.6.4.4. Southern Africa

7.6.5. Latin America

7.6.5.1. Brazil

7.6.5.2. Argentina

8. Global Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts

8.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

8.2.1. Dogs

8.2.1.1. Definition

8.2.1.2. Market Penetration, 2018

8.2.1.3. Market Estimation, 2013 – 2018

8.2.1.4. Market Forecast, 2019 – 2027

8.2.1.5. Compound Annual Growth Rate (CAGR)

8.2.1.6. Regional Bifurcation

8.2.1.6.1. North America

8.2.1.6.1.1. Market Estimation, 2013 – 2018

8.2.1.6.1.2. Market Forecast, 2019 – 2027

8.2.1.6.2. Europe

8.2.1.6.2.1. Market Estimation, 2013 – 2018

8.2.1.6.2.2. Market Forecast, 2019 – 2027

8.2.1.6.3. Asia Pacific

8.2.1.6.3.1. Market Estimation, 2013 – 2018

8.2.1.6.3.2. Market Forecast, 2019 – 2027

8.2.1.6.4. Middle East and Africa

8.2.1.6.4.1. Market Estimation, 2013 – 2018

8.2.1.6.4.2. Market Forecast, 2019 – 2027

8.2.1.6.5. Latin America

8.2.1.6.5.1. Market Estimation, 2013 – 2018

8.2.1.6.5.2. Market Forecast, 2019 – 2027

8.2.2. Cats

8.2.2.1. Definition

8.2.2.2. Market Penetration, 2018

8.2.2.3. Market Estimation, 2013 – 2018

8.2.2.4. Market Forecast, 2019 – 2027

8.2.2.5. Compound Annual Growth Rate (CAGR)

8.2.2.6. Regional Bifurcation

8.2.2.6.1. North America

8.2.2.6.1.1. Market Estimation, 2013 – 2018

8.2.2.6.1.2. Market Forecast, 2019 – 2027

8.2.2.6.2. Europe

8.2.2.6.2.1. Market Estimation, 2013 – 2018

8.2.2.6.2.2. Market Forecast, 2019 – 2027

8.2.2.6.3. Asia Pacific

8.2.2.6.3.1. Market Estimation, 2013 – 2018

8.2.2.6.3.2. Market Forecast, 2019 – 2027

8.2.2.6.4. Middle East and Africa

8.2.2.6.4.1. Market Estimation, 2013 – 2018

8.2.2.6.4.2. Market Forecast, 2019 – 2027

8.2.2.6.5. Latin America

8.2.2.6.5.1. Market Estimation, 2013 – 2018

8.2.2.6.5.2. Market Forecast, 2019 – 2027

8.2.3. Horses

8.2.3.1. Definition

8.2.3.2. Market Penetration, 2018

8.2.3.3. Market Estimation, 2013 – 2018

8.2.3.4. Market Forecast, 2019 – 2027

8.2.3.5. Compound Annual Growth Rate (CAGR)

8.2.3.6. Regional Bifurcation

8.2.3.6.1. North America

8.2.3.6.1.1. Market Estimation, 2013 – 2018

8.2.3.6.1.2. Market Forecast, 2019 – 2027

8.2.3.6.2. Europe

8.2.3.6.2.1. Market Estimation, 2013 – 2018

8.2.3.6.2.2. Market Forecast, 2019 – 2027

8.2.3.6.3. Asia Pacific

8.2.3.6.3.1. Market Estimation, 2013 – 2018

8.2.3.6.3.2. Market Forecast, 2019 – 2027

8.2.3.6.4. Middle East and Africa

8.2.3.6.4.1. Market Estimation, 2013 – 2018

8.2.3.6.4.2. Market Forecast, 2019 – 2027

8.2.3.6.5. Latin America

8.2.3.6.5.1. Market Estimation, 2013 – 2018

8.2.3.6.5.2. Market Forecast, 2019 – 2027

8.2.4. Others

8.2.4.1. Definition

8.2.4.2. Market Penetration, 2018

8.2.4.3. Market Estimation, 2013 – 2018

8.2.4.4. Market Forecast, 2019 – 2027

8.2.4.5. Compound Annual Growth Rate (CAGR)

8.2.4.6. Regional Bifurcation

8.2.4.6.1. North America

8.2.4.6.1.1. Market Estimation, 2013 – 2018

8.2.4.6.1.2. Market Forecast, 2019 – 2027

8.2.4.6.2. Europe

8.2.4.6.2.1. Market Estimation, 2013 – 2018

8.2.4.6.2.2. Market Forecast, 2019 – 2027

8.2.4.6.3. Asia Pacific

8.2.4.6.3.1. Market Estimation, 2013 – 2018

8.2.4.6.3.2. Market Forecast, 2019 – 2027

8.2.4.6.4. Middle East and Africa

8.2.4.6.4.1. Market Estimation, 2013 – 2018

8.2.4.6.4.2. Market Forecast, 2019 – 2027

8.2.4.6.5. Latin America

8.2.4.6.5.1. Market Estimation, 2013 – 2018

8.2.4.6.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Animal Type

9. Global Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

9.2.1. Mast Cell Cancer

9.2.1.1. Definition

9.2.1.2. Market Penetration, 2018

9.2.1.3. Market Estimation, 2013 – 2018

9.2.1.4. Market Forecast, 2019 – 2027

9.2.1.5. Compound Annual Growth Rate (CAGR)

9.2.1.6. Regional Bifurcation

9.2.1.6.1. North America

9.2.1.6.1.1. Market Estimation, 2013 – 2018

9.2.1.6.1.2. Market Forecast, 2019 – 2027

9.2.1.6.2. Europe

9.2.1.6.2.1. Market Estimation, 2013 – 2018

9.2.1.6.2.2. Market Forecast, 2019 – 2027

9.2.1.6.3. Asia Pacific

9.2.1.6.3.1. Market Estimation, 2013 – 2018

9.2.1.6.3.2. Market Forecast, 2019 – 2027

9.2.1.6.4. Middle East and Africa

9.2.1.6.4.1. Market Estimation, 2013 – 2018

9.2.1.6.4.2. Market Forecast, 2019 – 2027

9.2.1.6.5. Latin America

9.2.1.6.5.1. Market Estimation, 2013 – 2018

9.2.1.6.5.2. Market Forecast, 2019 – 2027

9.2.2. Lymphoma

9.2.2.1. Definition

9.2.2.2. Market Penetration, 2018

9.2.2.3. Market Estimation, 2013 – 2018

9.2.2.4. Market Forecast, 2019 – 2027

9.2.2.5. Compound Annual Growth Rate (CAGR)

9.2.2.6. Regional Bifurcation

9.2.2.6.1. North America

9.2.2.6.1.1. Market Estimation, 2013 – 2018

9.2.2.6.1.2. Market Forecast, 2019 – 2027

9.2.2.6.2. Europe

9.2.2.6.2.1. Market Estimation, 2013 – 2018

9.2.2.6.2.2. Market Forecast, 2019 – 2027

9.2.2.6.3. Asia Pacific

9.2.2.6.3.1. Market Estimation, 2013 – 2018

9.2.2.6.3.2. Market Forecast, 2019 – 2027

9.2.2.6.4. Middle East and Africa

9.2.2.6.4.1. Market Estimation, 2013 – 2018

9.2.2.6.4.2. Market Forecast, 2019 – 2027

9.2.2.6.5. Latin America

9.2.2.6.5.1. Market Estimation, 2013 – 2018

9.2.2.6.5.2. Market Forecast, 2019 – 2027

9.2.3. Melanoma

9.2.3.1. Definition

9.2.3.2. Market Penetration, 2018

9.2.3.3. Market Estimation, 2013 – 2018

9.2.3.4. Market Forecast, 2019 – 2027

9.2.3.5. Compound Annual Growth Rate (CAGR)

9.2.3.6. Regional Bifurcation

9.2.3.6.1. North America

9.2.3.6.1.1. Market Estimation, 2013 – 2018

9.2.3.6.1.2. Market Forecast, 2019 – 2027

9.2.3.6.2. Europe

9.2.3.6.2.1. Market Estimation, 2013 – 2018

9.2.3.6.2.2. Market Forecast, 2019 – 2027

9.2.3.6.3. Asia Pacific

9.2.3.6.3.1. Market Estimation, 2013 – 2018

9.2.3.6.3.2. Market Forecast, 2019 – 2027

9.2.3.6.4. Middle East and Africa

9.2.3.6.4.1. Market Estimation, 2013 – 2018

9.2.3.6.4.2. Market Forecast, 2019 – 2027

9.2.3.6.5. Latin America

9.2.3.6.5.1. Market Estimation, 2013 – 2018

9.2.3.6.5.2. Market Forecast, 2019 – 2027

9.2.4. Mammary

9.2.4.1. Definition

9.2.4.2. Market Penetration, 2018

9.2.4.3. Market Estimation, 2013 – 2018

9.2.4.4. Market Forecast, 2019 – 2027

9.2.4.5. Compound Annual Growth Rate (CAGR)

9.2.4.6. Regional Bifurcation

9.2.4.6.1. North America

9.2.4.6.1.1. Market Estimation, 2013 – 2018

9.2.4.6.1.2. Market Forecast, 2019 – 2027

9.2.4.6.2. Europe

9.2.4.6.2.1. Market Estimation, 2013 – 2018

9.2.4.6.2.2. Market Forecast, 2019 – 2027

9.2.4.6.3. Asia Pacific

9.2.4.6.3.1. Market Estimation, 2013 – 2018

9.2.4.6.3.2. Market Forecast, 2019 – 2027

9.2.4.6.4. Middle East and Africa

9.2.4.6.4.1. Market Estimation, 2013 – 2018

9.2.4.6.4.2. Market Forecast, 2019 – 2027

9.2.4.6.5. Latin America

9.2.4.6.5.1. Market Estimation, 2013 – 2018

9.2.4.6.5.2. Market Forecast, 2019 – 2027

9.2.5. Squamous Cell Cancer

9.2.5.1. Definition

9.2.5.2. Market Penetration, 2018

9.2.5.3. Market Estimation, 2013 – 2018

9.2.5.4. Market Forecast, 2019 – 2027

9.2.5.5. Compound Annual Growth Rate (CAGR)

9.2.5.6. Regional Bifurcation

9.2.5.6.1. North America

9.2.5.6.1.1. Market Estimation, 2013 – 2018

9.2.5.6.1.2. Market Forecast, 2019 – 2027

9.2.5.6.2. Europe

9.2.5.6.2.1. Market Estimation, 2013 – 2018

9.2.5.6.2.2. Market Forecast, 2019 – 2027

9.2.5.6.3. Asia Pacific

9.2.5.6.3.1. Market Estimation, 2013 – 2018

9.2.5.6.3.2. Market Forecast, 2019 – 2027

9.2.5.6.4. Middle East and Africa

9.2.5.6.4.1. Market Estimation, 2013 – 2018

9.2.5.6.4.2. Market Forecast, 2019 – 2027

9.2.5.6.5. Latin America

9.2.5.6.5.1. Market Estimation, 2013 – 2018

9.2.5.6.5.2. Market Forecast, 2019 – 2027

9.2.6. Others

9.2.6.1. Definition

9.2.6.2. Market Penetration, 2018

9.2.6.3. Market Estimation, 2013 – 2018

9.2.6.4. Market Forecast, 2019 – 2027

9.2.6.5. Compound Annual Growth Rate (CAGR)

9.2.6.6. Regional Bifurcation

9.2.6.6.1. North America

9.2.6.6.1.1. Market Estimation, 2013 – 2018

9.2.6.6.1.2. Market Forecast, 2019 – 2027

9.2.6.6.2. Europe

9.2.6.6.2.1. Market Estimation, 2013 – 2018

9.2.6.6.2.2. Market Forecast, 2019 – 2027

9.2.6.6.3. Asia Pacific

9.2.6.6.3.1. Market Estimation, 2013 – 2018

9.2.6.6.3.2. Market Forecast, 2019 – 2027

9.2.6.6.4. Middle East and Africa

9.2.6.6.4.1. Market Estimation, 2013 – 2018

9.2.6.6.4.2. Market Forecast, 2019 – 2027

9.2.6.6.5. Latin America

9.2.6.6.5.1. Market Estimation, 2013 – 2018

9.2.6.6.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Cancer Type

10. Global Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

10.1. Overview

10.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

10.2.1. Oral

10.2.1.1. Definition

10.2.1.2. Market Penetration, 2018

10.2.1.3. Market Estimation, 2013 – 2018

10.2.1.4. Market Forecast, 2019 – 2027

10.2.1.5. Compound Annual Growth Rate (CAGR)

10.2.1.6. Regional Bifurcation

10.2.1.6.1. North America

10.2.1.6.1.1. Market Estimation, 2013 – 2018

10.2.1.6.1.2. Market Forecast, 2019 – 2027

10.2.1.6.2. Europe

10.2.1.6.2.1. Market Estimation, 2013 – 2018

10.2.1.6.2.2. Market Forecast, 2019 – 2027

10.2.1.6.3. Asia Pacific

10.2.1.6.3.1. Market Estimation, 2013 – 2018

10.2.1.6.3.2. Market Forecast, 2019 – 2027

10.2.1.6.4. Middle East and Africa

10.2.1.6.4.1. Market Estimation, 2013 – 2018

10.2.1.6.4.2. Market Forecast, 2019 – 2027

10.2.1.6.5. Latin America

10.2.1.6.5.1. Market Estimation, 2013 – 2018

10.2.1.6.5.2. Market Forecast, 2019 – 2027

10.2.2. Intravenous

10.2.2.1. Definition

10.2.2.2. Market Penetration, 2018

10.2.2.3. Market Estimation, 2013 – 2018

10.2.2.4. Market Forecast, 2019 – 2027

10.2.2.5. Compound Annual Growth Rate (CAGR)

10.2.2.6. Regional Bifurcation

10.2.2.6.1. North America

10.2.2.6.1.1. Market Estimation, 2013 – 2018

10.2.2.6.1.2. Market Forecast, 2019 – 2027

10.2.2.6.2. Europe

10.2.2.6.2.1. Market Estimation, 2013 – 2018

10.2.2.6.2.2. Market Forecast, 2019 – 2027

10.2.2.6.3. Asia Pacific

10.2.2.6.3.1. Market Estimation, 2013 – 2018

10.2.2.6.3.2. Market Forecast, 2019 – 2027

10.2.2.6.4. Middle East and Africa

10.2.2.6.4.1. Market Estimation, 2013 – 2018

10.2.2.6.4.2. Market Forecast, 2019 – 2027

10.2.2.6.5. Latin America

10.2.2.6.5.1. Market Estimation, 2013 – 2018

10.2.2.6.5.2. Market Forecast, 2019 – 2027

10.2.3. Others

10.2.3.1. Definition

10.2.3.2. Market Penetration, 2018

10.2.3.3. Market Estimation, 2013 – 2018

10.2.3.4. Market Forecast, 2019 – 2027

10.2.3.5. Compound Annual Growth Rate (CAGR)

10.2.3.6. Regional Bifurcation

10.2.3.6.1. North America

10.2.3.6.1.1. Market Estimation, 2013 – 2018

10.2.3.6.1.2. Market Forecast, 2019 – 2027

10.2.3.6.2. Europe

10.2.3.6.2.1. Market Estimation, 2013 – 2018

10.2.3.6.2.2. Market Forecast, 2019 – 2027

10.2.3.6.3. Asia Pacific

10.2.3.6.3.1. Market Estimation, 2013 – 2018

10.2.3.6.3.2. Market Forecast, 2019 – 2027

10.2.3.6.4. Middle East and Africa

10.2.3.6.4.1. Market Estimation, 2013 – 2018

10.2.3.6.4.2. Market Forecast, 2019 – 2027

10.2.3.6.5. Latin America

10.2.3.6.5.1. Market Estimation, 2013 – 2018

10.2.3.6.5.2. Market Forecast, 2019 – 2027

10.3. Key Segment for Channeling Investments

10.3.1. By Route of Administration

11. Global Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

11.1. Overview

11.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

11.2.1. Chemotherapy

11.2.1.1. Definition

11.2.1.2. Market Penetration, 2018

11.2.1.3. Market Estimation, 2013 – 2018

11.2.1.4. Market Forecast, 2019 – 2027

11.2.1.5. Compound Annual Growth Rate (CAGR)

11.2.1.6. Regional Bifurcation

11.2.1.6.1. North America

11.2.1.6.1.1. Market Estimation, 2013 – 2018

11.2.1.6.1.2. Market Forecast, 2019 – 2027

11.2.1.6.2. Europe

11.2.1.6.2.1. Market Estimation, 2013 – 2018

11.2.1.6.2.2. Market Forecast, 2019 – 2027

11.2.1.6.3. Asia Pacific

11.2.1.6.3.1. Market Estimation, 2013 – 2018

11.2.1.6.3.2. Market Forecast, 2019 – 2027

11.2.1.6.4. Middle East and Africa

11.2.1.6.4.1. Market Estimation, 2013 – 2018

11.2.1.6.4.2. Market Forecast, 2019 – 2027

11.2.1.6.5. Latin America

11.2.1.6.5.1. Market Estimation, 2013 – 2018

11.2.1.6.5.2. Market Forecast, 2019 – 2027

11.2.2. Targeted Therapy

11.2.2.1. Definition

11.2.2.2. Market Penetration, 2018

11.2.2.3. Market Estimation, 2013 – 2018

11.2.2.4. Market Forecast, 2019 – 2027

11.2.2.5. Compound Annual Growth Rate (CAGR)

11.2.2.6. Regional Bifurcation

11.2.2.6.1. North America

11.2.2.6.1.1. Market Estimation, 2013 – 2018

11.2.2.6.1.2. Market Forecast, 2019 – 2027

11.2.2.6.2. Europe

11.2.2.6.2.1. Market Estimation, 2013 – 2018

11.2.2.6.2.2. Market Forecast, 2019 – 2027

11.2.2.6.3. Asia Pacific

11.2.2.6.3.1. Market Estimation, 2013 – 2018

11.2.2.6.3.2. Market Forecast, 2019 – 2027

11.2.2.6.4. Middle East and Africa

11.2.2.6.4.1. Market Estimation, 2013 – 2018

11.2.2.6.4.2. Market Forecast, 2019 – 2027

11.2.2.6.5. Latin America

11.2.2.6.5.1. Market Estimation, 2013 – 2018

11.2.2.6.5.2. Market Forecast, 2019 – 2027

11.2.3. Combination Therapy

11.2.3.1. Definition

11.2.3.2. Market Penetration, 2018

11.2.3.3. Market Estimation, 2013 – 2018

11.2.3.4. Market Forecast, 2019 – 2027

11.2.3.5. Compound Annual Growth Rate (CAGR)

11.2.3.6. Regional Bifurcation

11.2.3.6.1. North America

11.2.3.6.1.1. Market Estimation, 2013 – 2018

11.2.3.6.1.2. Market Forecast, 2019 – 2027

11.2.3.6.2. Europe

11.2.3.6.2.1. Market Estimation, 2013 – 2018

11.2.3.6.2.2. Market Forecast, 2019 – 2027

11.2.3.6.3. Asia Pacific

11.2.3.6.3.1. Market Estimation, 2013 – 2018

11.2.3.6.3.2. Market Forecast, 2019 – 2027

11.2.3.6.4. Middle East and Africa

11.2.3.6.4.1. Market Estimation, 2013 – 2018

11.2.3.6.4.2. Market Forecast, 2019 – 2027

11.2.3.6.5. Latin America

11.2.3.6.5.1. Market Estimation, 2013 – 2018

11.2.3.6.5.2. Market Forecast, 2019 – 2027

11.2.4. Immunotherapy

11.2.4.1. Definition

11.2.4.2. Market Penetration, 2018

11.2.4.3. Market Estimation, 2013 – 2018

11.2.4.4. Market Forecast, 2019 – 2027

11.2.4.5. Compound Annual Growth Rate (CAGR)

11.2.4.6. Regional Bifurcation

11.2.4.6.1. North America

11.2.4.6.1.1. Market Estimation, 2013 – 2018

11.2.4.6.1.2. Market Forecast, 2019 – 2027

11.2.4.6.2. Europe

11.2.4.6.2.1. Market Estimation, 2013 – 2018

11.2.4.6.2.2. Market Forecast, 2019 – 2027

11.2.4.6.3. Asia Pacific

11.2.4.6.3.1. Market Estimation, 2013 – 2018

11.2.4.6.3.2. Market Forecast, 2019 – 2027

11.2.4.6.4. Middle East and Africa

11.2.4.6.4.1. Market Estimation, 2013 – 2018

11.2.4.6.4.2. Market Forecast, 2019 – 2027

11.2.4.6.5. Latin America

11.2.4.6.5.1. Market Estimation, 2013 – 2018

11.2.4.6.5.2. Market Forecast, 2019 – 2027

11.3. Key Segment for Channeling Investments

11.3.1. By Therapy Type

12. North America Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

12.1. Overview

12.1.1. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units)

12.2. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

12.2.1. Dogs

12.2.2. Cats

12.2.3. Horses

12.2.4. Others

12.3. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

12.3.1. Mast Cell Cancer

12.3.2. Lymphoma

12.3.3. Melanoma

12.3.4. Mammary

12.3.5. Squamous Cell Cancer

12.3.6. Others

12.4. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

12.4.1. Oral

12.4.2. Intravenous

12.4.3. Others

12.5. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

12.5.1. Chemotherapy

12.5.2. Targeted Therapy

12.5.3. Combination Therapy

12.5.4. Immunotherapy

12.6. North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

12.6.1. U.S.

12.6.1.1. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

12.6.1.1.1. Dogs

12.6.1.1.2. Cats

12.6.1.1.3. Horses

12.6.1.1.4. Others

12.6.1.2. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

12.6.1.2.1. Mast Cell Cancer

12.6.1.2.2. Lymphoma

12.6.1.2.3. Melanoma

12.6.1.2.4. Mammary

12.6.1.2.5. Squamous Cell Cancer

12.6.1.2.6. Others

12.6.1.3. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

12.6.1.3.1. Oral

12.6.1.3.2. Intravenous

12.6.1.3.3. Others

12.6.1.4. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

12.6.1.4.1. Chemotherapy

12.6.1.4.2. Targeted Therapy

12.6.1.4.3. Combination Therapy

12.6.1.4.4. Immunotherapy

12.6.2. Canada

12.6.2.1. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

12.6.2.1.1. Dogs

12.6.2.1.2. Cats

12.6.2.1.3. Horses

12.6.2.1.4. Others

12.6.2.2. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

12.6.2.2.1. Mast Cell Cancer

12.6.2.2.2. Lymphoma

12.6.2.2.3. Melanoma

12.6.2.2.4. Mammary

12.6.2.2.5. Squamous Cell Cancer

12.6.2.2.6. Others

12.6.2.3. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

12.6.2.3.1. Oral

12.6.2.3.2. Intravenous

12.6.2.3.3. Others

12.6.2.4. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

12.6.2.4.1. Chemotherapy

12.6.2.4.2. Targeted Therapy

12.6.2.4.3. Combination Therapy

12.6.2.4.4. Immunotherapy

12.6.3. Mexico

12.6.3.1. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

12.6.3.1.1. Dogs

12.6.3.1.2. Cats

12.6.3.1.3. Horses

12.6.3.1.4. Others

12.6.3.2. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

12.6.3.2.1. Mast Cell Cancer

12.6.3.2.2. Lymphoma

12.6.3.2.3. Melanoma

12.6.3.2.4. Mammary

12.6.3.2.5. Squamous Cell Cancer

12.6.3.2.6. Others

12.6.3.3. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

12.6.3.3.1. Oral

12.6.3.3.2. Intravenous

12.6.3.3.3. Others

12.6.3.4. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

12.6.3.4.1. Chemotherapy

12.6.3.4.2. Targeted Therapy

12.6.3.4.3. Combination Therapy

12.6.3.4.4. Immunotherapy

12.6.4. Rest of North America

12.6.4.1. Rest of North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

12.6.4.1.1. Dogs

12.6.4.1.2. Cats

12.6.4.1.3. Horses

12.6.4.1.4. Others

12.6.4.2. Rest of North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

12.6.4.2.1. Mast Cell Cancer

12.6.4.2.2. Lymphoma

12.6.4.2.3. Melanoma

12.6.4.2.4. Mammary

12.6.4.2.5. Squamous Cell Cancer

12.6.4.2.6. Others

12.6.4.3. Rest of North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

12.6.4.3.1. Oral

12.6.4.3.2. Intravenous

12.6.4.3.3. Others

12.6.4.4. Rest of North America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

12.6.4.4.1. Chemotherapy

12.6.4.4.2. Targeted Therapy

12.6.4.4.3. Combination Therapy

12.6.4.4.4. Immunotherapy

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Animal Type

12.7.3. By Cancer Type

12.7.4. By Route of Administration

12.7.5. By Therapy Type

13. Europe Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

13.1. Overview

13.1.1. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units)

13.2. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.2.1. Dogs

13.2.2. Cats

13.2.3. Horses

13.2.4. Others

13.3. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.3.1. Mast Cell Cancer

13.3.2. Lymphoma

13.3.3. Melanoma

13.3.4. Mammary

13.3.5. Squamous Cell Cancer

13.3.6. Others

13.4. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.4.1. Oral

13.4.2. Intravenous

13.4.3. Others

13.5. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.5.1. Chemotherapy

13.5.2. Targeted Therapy

13.5.3. Combination Therapy

13.5.4. Immunotherapy

13.6. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

13.6.1. France

13.6.1.1. France Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.1.1.1. Dogs

13.6.1.1.2. Cats

13.6.1.1.3. Horses

13.6.1.1.4. Others

13.6.1.2. France Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.1.2.1. Mast Cell Cancer

13.6.1.2.2. Lymphoma

13.6.1.2.3. Melanoma

13.6.1.2.4. Mammary

13.6.1.2.5. Squamous Cell Cancer

13.6.1.2.6. Others

13.6.1.3. France Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.1.3.1. Oral

13.6.1.3.2. Intravenous

13.6.1.3.3. Others

13.6.1.4. France Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.1.4.1. Chemotherapy

13.6.1.4.2. Targeted Therapy

13.6.1.4.3. Combination Therapy

13.6.1.4.4. Immunotherapy

13.6.2. The UK

13.6.2.1. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.2.1.1. Dogs

13.6.2.1.2. Cats

13.6.2.1.3. Horses

13.6.2.1.4. Others

13.6.2.2. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.2.2.1. Mast Cell Cancer

13.6.2.2.2. Lymphoma

13.6.2.2.3. Melanoma

13.6.2.2.4. Mammary

13.6.2.2.5. Squamous Cell Cancer

13.6.2.2.6. Others

13.6.2.3. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.2.3.1. Oral

13.6.2.3.2. Intravenous

13.6.2.3.3. Others

13.6.2.4. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.2.4.1. Chemotherapy

13.6.2.4.2. Targeted Therapy

13.6.2.4.3. Combination Therapy

13.6.2.4.4. Immunotherapy

13.6.3. Spain

13.6.3.1. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.3.1.1. Dogs

13.6.3.1.2. Cats

13.6.3.1.3. Horses

13.6.3.1.4. Others

13.6.3.2. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.3.2.1. Mast Cell Cancer

13.6.3.2.2. Lymphoma

13.6.3.2.3. Melanoma

13.6.3.2.4. Mammary

13.6.3.2.5. Squamous Cell Cancer

13.6.3.2.6. Others

13.6.3.3. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.3.3.1. Oral

13.6.3.3.2. Intravenous

13.6.3.3.3. Others

13.6.3.4. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.3.4.1. Chemotherapy

13.6.3.4.2. Targeted Therapy

13.6.3.4.3. Combination Therapy

13.6.3.4.4. Immunotherapy

13.6.4. Germany

13.6.4.1. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.4.1.1. Dogs

13.6.4.1.2. Cats

13.6.4.1.3. Horses

13.6.4.1.4. Others

13.6.4.2. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.4.2.1. Mast Cell Cancer

13.6.4.2.2. Lymphoma

13.6.4.2.3. Melanoma

13.6.4.2.4. Mammary

13.6.4.2.5. Squamous Cell Cancer

13.6.4.2.6. Others

13.6.4.3. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.4.3.1. Oral

13.6.4.3.2. Intravenous

13.6.4.3.3. Others

13.6.4.4. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.4.4.1. Chemotherapy

13.6.4.4.2. Targeted Therapy

13.6.4.4.3. Combination Therapy

13.6.4.4.4. Immunotherapy

13.6.5. Italy

13.6.5.1. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.5.1.1. Dogs

13.6.5.1.2. Cats

13.6.5.1.3. Horses

13.6.5.1.4. Others

13.6.5.2. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.5.2.1. Mast Cell Cancer

13.6.5.2.2. Lymphoma

13.6.5.2.3. Melanoma

13.6.5.2.4. Mammary

13.6.5.2.5. Squamous Cell Cancer

13.6.5.2.6. Others

13.6.5.3. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.5.3.1. Oral

13.6.5.3.2. Intravenous

13.6.5.3.3. Others

13.6.5.4. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.5.4.1. Chemotherapy

13.6.5.4.2. Targeted Therapy

13.6.5.4.3. Combination Therapy

13.6.5.4.4. Immunotherapy

13.6.6. Nordic Countries

13.6.6.1. Nordic Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.6.1.1. Dogs

13.6.6.1.2. Cats

13.6.6.1.3. Horses

13.6.6.1.4. Others

13.6.6.2. Nordic Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.6.2.1. Mast Cell Cancer

13.6.6.2.2. Lymphoma

13.6.6.2.3. Melanoma

13.6.6.2.4. Mammary

13.6.6.2.5. Squamous Cell Cancer

13.6.6.2.6. Others

13.6.6.3. Nordic Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.6.3.1. Oral

13.6.6.3.2. Intravenous

13.6.6.3.3. Others

13.6.6.4. Nordic Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.6.4.1. Chemotherapy

13.6.6.4.2. Targeted Therapy

13.6.6.4.3. Combination Therapy

13.6.6.4.4. Immunotherapy

13.6.6.5. Nordic Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

13.6.6.5.1. Finland

13.6.6.5.2. Denmark

13.6.6.5.3. Norway

13.6.6.5.4. Sweden

13.6.6.5.5. Iceland

13.6.6.5.6. Rest of Nordic Countries

13.6.7. The Benelux Union

13.6.7.1. The Benelux Union Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.7.1.1. Dogs

13.6.7.1.2. Cats

13.6.7.1.3. Horses

13.6.7.1.4. Others

13.6.7.2. The Benelux Union Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.7.2.1. Mast Cell Cancer

13.6.7.2.2. Lymphoma

13.6.7.2.3. Melanoma

13.6.7.2.4. Mammary

13.6.7.2.5. Squamous Cell Cancer

13.6.7.2.6. Others

13.6.7.3. The Benelux Union Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.7.3.1. Oral

13.6.7.3.2. Intravenous

13.6.7.3.3. Others

13.6.7.4. The Benelux Union Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.7.4.1. Chemotherapy

13.6.7.4.2. Targeted Therapy

13.6.7.4.3. Combination Therapy

13.6.7.4.4. Immunotherapy

13.6.7.5. The Benelux Union Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.7.5.1. Belgium

13.6.7.5.2. The Netherlands

13.6.7.5.3. Luxemburg

13.6.8. Rest of Europe

13.6.8.1. Rest of Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

13.6.8.1.1. Dogs

13.6.8.1.2. Cats

13.6.8.1.3. Horses

13.6.8.1.4. Others

13.6.8.2. Rest of Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

13.6.8.2.1. Mast Cell Cancer

13.6.8.2.2. Lymphoma

13.6.8.2.3. Melanoma

13.6.8.2.4. Mammary

13.6.8.2.5. Squamous Cell Cancer

13.6.8.2.6. Others

13.6.8.3. Rest of Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

13.6.8.3.1. Oral

13.6.8.3.2. Intravenous

13.6.8.3.3. Others

13.6.8.4. Rest of Europe Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

13.6.8.4.1. Chemotherapy

13.6.8.4.2. Targeted Therapy

13.6.8.4.3. Combination Therapy

13.6.8.4.4. Immunotherapy

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Animal Type

13.7.3. By Cancer Type

13.7.4. By Route of Administration

13.7.5. By Therapy Type

14. Asia Pacific Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

14.1. Overview

14.1.1. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units)

14.2. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.2.1. Dogs

14.2.2. Cats

14.2.3. Horses

14.2.4. Others

14.3. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.3.1. Mast Cell Cancer

14.3.2. Lymphoma

14.3.3. Melanoma

14.3.4. Mammary

14.3.5. Squamous Cell Cancer

14.3.6. Others

14.4. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.4.1. Oral

14.4.2. Intravenous

14.4.3. Others

14.5. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.5.1. Chemotherapy

14.5.2. Targeted Therapy

14.5.3. Combination Therapy

14.5.4. Immunotherapy

14.6. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

14.6.1. China

14.6.1.1. China Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.1.1.1. Dogs

14.6.1.1.2. Cats

14.6.1.1.3. Horses

14.6.1.1.4. Others

14.6.1.2. China Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.1.2.1. Mast Cell Cancer

14.6.1.2.2. Lymphoma

14.6.1.2.3. Melanoma

14.6.1.2.4. Mammary

14.6.1.2.5. Squamous Cell Cancer

14.6.1.2.6. Others

14.6.1.3. China Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.1.3.1. Oral

14.6.1.3.2. Intravenous

14.6.1.3.3. Others

14.6.1.4. China Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.1.4.1. Chemotherapy

14.6.1.4.2. Targeted Therapy

14.6.1.4.3. Combination Therapy

14.6.1.4.4. Immunotherapy

14.6.2. Japan

14.6.2.1. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.2.1.1. Dogs

14.6.2.1.2. Cats

14.6.2.1.3. Horses

14.6.2.1.4. Others

14.6.2.2. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.2.2.1. Mast Cell Cancer

14.6.2.2.2. Lymphoma

14.6.2.2.3. Melanoma

14.6.2.2.4. Mammary

14.6.2.2.5. Squamous Cell Cancer

14.6.2.2.6. Others

14.6.2.3. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.2.3.1. Oral

14.6.2.3.2. Intravenous

14.6.2.3.3. Others

14.6.2.4. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.2.4.1. Chemotherapy

14.6.2.4.2. Targeted Therapy

14.6.2.4.3. Combination Therapy

14.6.2.4.4. Immunotherapy

14.6.3. India

14.6.3.1. India Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.3.1.1. Dogs

14.6.3.1.2. Cats

14.6.3.1.3. Horses

14.6.3.1.4. Others

14.6.3.2. India Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.3.2.1. Mast Cell Cancer

14.6.3.2.2. Lymphoma

14.6.3.2.3. Melanoma

14.6.3.2.4. Mammary

14.6.3.2.5. Squamous Cell Cancer

14.6.3.2.6. Others

14.6.3.3. India Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.3.3.1. Oral

14.6.3.3.2. Intravenous

14.6.3.3.3. Others

14.6.3.4. India Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.3.4.1. Chemotherapy

14.6.3.4.2. Targeted Therapy

14.6.3.4.3. Combination Therapy

14.6.3.4.4. Immunotherapy

14.6.4. Australia

14.6.4.1. Australia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.4.1.1. Dogs

14.6.4.1.2. Cats

14.6.4.1.3. Horses

14.6.4.1.4. Others

14.6.4.2. Australia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.4.2.1. Mast Cell Cancer

14.6.4.2.2. Lymphoma

14.6.4.2.3. Melanoma

14.6.4.2.4. Mammary

14.6.4.2.5. Squamous Cell Cancer

14.6.4.2.6. Others

14.6.4.3. Australia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.4.3.1. Oral

14.6.4.3.2. Intravenous

14.6.4.3.3. Others

14.6.4.4. Australia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.4.4.1. Chemotherapy

14.6.4.4.2. Targeted Therapy

14.6.4.4.3. Combination Therapy

14.6.4.4.4. Immunotherapy

14.6.5. New Zealand

14.6.5.1. New Zealand Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.5.1.1. Dogs

14.6.5.1.2. Cats

14.6.5.1.3. Horses

14.6.5.1.4. Others

14.6.5.2. New Zealand Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.5.2.1. Mast Cell Cancer

14.6.5.2.2. Lymphoma

14.6.5.2.3. Melanoma

14.6.5.2.4. Mammary

14.6.5.2.5. Squamous Cell Cancer

14.6.5.2.6. Others

14.6.5.3. New Zealand Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.5.3.1. Oral

14.6.5.3.2. Intravenous

14.6.5.3.3. Others

14.6.5.4. New Zealand Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.5.4.1. Chemotherapy

14.6.5.4.2. Targeted Therapy

14.6.5.4.3. Combination Therapy

14.6.5.4.4. Immunotherapy

14.6.6. Southeast Asia

14.6.6.1. Southeast Asia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.6.1.1. Dogs

14.6.6.1.2. Cats

14.6.6.1.3. Horses

14.6.6.1.4. Others

14.6.6.2. Southeast Asia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.6.2.1. Mast Cell Cancer

14.6.6.2.2. Lymphoma

14.6.6.2.3. Melanoma

14.6.6.2.4. Mammary

14.6.6.2.5. Squamous Cell Cancer

14.6.6.2.6. Others

14.6.6.3. Southeast Asia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.6.3.1. Oral

14.6.6.3.2. Intravenous

14.6.6.3.3. Others

14.6.6.4. Southeast Asia Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.6.4.1. Chemotherapy

14.6.6.4.2. Targeted Therapy

14.6.6.4.3. Combination Therapy

14.6.6.4.4. Immunotherapy

14.6.7. Rest of Asia Pacific

14.6.7.1. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

14.6.7.1.1. Dogs

14.6.7.1.2. Cats

14.6.7.1.3. Horses

14.6.7.1.4. Others

14.6.7.2. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

14.6.7.2.1. Mast Cell Cancer

14.6.7.2.2. Lymphoma

14.6.7.2.3. Melanoma

14.6.7.2.4. Mammary

14.6.7.2.5. Squamous Cell Cancer

14.6.7.2.6. Others

14.6.7.3. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

14.6.7.3.1. Oral

14.6.7.3.2. Intravenous

14.6.7.3.3. Others

14.6.7.4. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

14.6.7.4.1. Chemotherapy

14.6.7.4.2. Targeted Therapy

14.6.7.4.3. Combination Therapy

14.6.7.4.4. Immunotherapy

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Animal Type

14.7.3. By Cancer Type

14.7.4. By Route of Administration

14.7.5. By Therapy Type





15. Middle East and Africa Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

15.1. Overview

15.1.1. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units)

15.2. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

15.2.1. Dogs

15.2.2. Cats

15.2.3. Horses

15.2.4. Others

15.3. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

15.3.1. Mast Cell Cancer

15.3.2. Lymphoma

15.3.3. Melanoma

15.3.4. Mammary

15.3.5. Squamous Cell Cancer

15.3.6. Others

15.4. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

15.4.1. Oral

15.4.2. Intravenous

15.4.3. Others

15.5. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

15.5.1. Chemotherapy

15.5.2. Targeted Therapy

15.5.3. Combination Therapy

15.5.4. Immunotherapy

15.6. Middle East and Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

15.6.1. GCC Countries

15.6.1.1. GCC Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

15.6.1.1.1. Dogs

15.6.1.1.2. Cats

15.6.1.1.3. Horses

15.6.1.1.4. Others

15.6.1.2. GCC Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

15.6.1.2.1. Mast Cell Cancer

15.6.1.2.2. Lymphoma

15.6.1.2.3. Melanoma

15.6.1.2.4. Mammary

15.6.1.2.5. Squamous Cell Cancer

15.6.1.2.6. Others

15.6.1.3. GCC Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

15.6.1.3.1. Oral

15.6.1.3.2. Intravenous

15.6.1.3.3. Others

15.6.1.4. GCC Countries Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

15.6.1.4.1. Chemotherapy

15.6.1.4.2. Targeted Therapy

15.6.1.4.3. Combination Therapy

15.6.1.4.4. Immunotherapy

15.6.2. Southern Africa

15.6.2.1. Southern Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

15.6.2.1.1. Dogs

15.6.2.1.2. Cats

15.6.2.1.3. Horses

15.6.2.1.4. Others

15.6.2.2. Southern Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

15.6.2.2.1. Mast Cell Cancer

15.6.2.2.2. Lymphoma

15.6.2.2.3. Melanoma

15.6.2.2.4. Mammary

15.6.2.2.5. Squamous Cell Cancer

15.6.2.2.6. Others

15.6.2.3. Southern Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

15.6.2.3.1. Oral

15.6.2.3.2. Intravenous

15.6.2.3.3. Others

15.6.2.4. Southern Africa Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

15.6.2.4.1. Chemotherapy

15.6.2.4.2. Targeted Therapy

15.6.2.4.3. Combination Therapy

15.6.2.4.4. Immunotherapy

15.6.3. Rest of MEA

15.6.3.1. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

15.6.3.1.1. Dogs

15.6.3.1.2. Cats

15.6.3.1.3. Horses

15.6.3.1.4. Others

15.6.3.2. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

15.6.3.2.1. Mast Cell Cancer

15.6.3.2.2. Lymphoma

15.6.3.2.3. Melanoma

15.6.3.2.4. Mammary

15.6.3.2.5. Squamous Cell Cancer

15.6.3.2.6. Others

15.6.3.3. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

15.6.3.3.1. Oral

15.6.3.3.2. Intravenous

15.6.3.3.3. Others

15.6.3.4. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

15.6.3.4.1. Chemotherapy

15.6.3.4.2. Targeted Therapy

15.6.3.4.3. Combination Therapy

15.6.3.4.4. Immunotherapy

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Animal Type

15.7.3. By Cancer Type

15.7.4. By Route of Administration

15.7.5. By Therapy Type

16. Latin America Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027

16.1. Overview

16.1.1. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units)

16.2. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

16.2.1. Dogs

16.2.2. Cats

16.2.3. Horses

16.2.4. Others

16.3. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

16.3.1. Mast Cell Cancer

16.3.2. Lymphoma

16.3.3. Melanoma

16.3.4. Mammary

16.3.5. Squamous Cell Cancer

16.3.6. Others

16.4. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

16.4.1. Oral

16.4.2. Intravenous

16.4.3. Others

16.5. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

16.5.1. Chemotherapy

16.5.2. Targeted Therapy

16.5.3. Combination Therapy

16.5.4. Immunotherapy

16.6. Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

16.6.1.1.1. Dogs

16.6.1.1.2. Cats

16.6.1.1.3. Horses

16.6.1.1.4. Others

16.6.1.2. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

16.6.1.2.1. Mast Cell Cancer

16.6.1.2.2. Lymphoma

16.6.1.2.3. Melanoma

16.6.1.2.4. Mammary

16.6.1.2.5. Squamous Cell Cancer

16.6.1.2.6. Others

16.6.1.3. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

16.6.1.3.1. Oral

16.6.1.3.2. Intravenous

16.6.1.3.3. Others

16.6.1.4. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

16.6.1.4.1. Chemotherapy

16.6.1.4.2. Targeted Therapy

16.6.1.4.3. Combination Therapy

16.6.1.4.4. Immunotherapy

16.6.2. Argentina

16.6.2.1. Argentina Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

16.6.2.1.1. Dogs

16.6.2.1.2. Cats

16.6.2.1.3. Horses

16.6.2.1.4. Others

16.6.2.2. Argentina Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

16.6.2.2.1. Mast Cell Cancer

16.6.2.2.2. Lymphoma

16.6.2.2.3. Melanoma

16.6.2.2.4. Mammary

16.6.2.2.5. Squamous Cell Cancer

16.6.2.2.6. Others

16.6.2.3. Argentina Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

16.6.2.3.1. Oral

16.6.2.3.2. Intravenous

16.6.2.3.3. Others

16.6.2.4. Argentina Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

16.6.2.4.1. Chemotherapy

16.6.2.4.2. Targeted Therapy

16.6.2.4.3. Combination Therapy

16.6.2.4.4. Immunotherapy

16.6.3. Rest of Latin America

16.6.3.1. Rest of Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Animal Type

16.6.3.1.1. Dogs

16.6.3.1.2. Cats

16.6.3.1.3. Horses

16.6.3.1.4. Others

16.6.3.2. Rest of Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type

16.6.3.2.1. Mast Cell Cancer

16.6.3.2.2. Lymphoma

16.6.3.2.3. Melanoma

16.6.3.2.4. Mammary

16.6.3.2.5. Squamous Cell Cancer

16.6.3.2.6. Others

16.6.3.3. Rest of Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration

16.6.3.3.1. Oral

16.6.3.3.2. Intravenous

16.6.3.3.3. Others

16.6.3.4. Rest of Latin America Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type

16.6.3.4.1. Chemotherapy

16.6.3.4.2. Targeted Therapy

16.6.3.4.3. Combination Therapy

16.6.3.4.4. Immunotherapy

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Animal Type

16.7.3. By Cancer Type

16.7.4. By Route of Administration

16.7.5. By Therapy Type

17. Competitive Benchmarking

17.1. Market Share Analysis, 2018

17.2. Global Presence and Growth Strategies

17.2.1. Mergers and Acquisitions

17.2.2. Product Launches

17.2.3. Investments Trends

17.2.4. R&D Initiatives

18. Player Profiles

18.1. AdvaVet

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. Advaxis Inc.

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. Amgen Inc.

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. Aratana Therapeutics, Inc.

18.4.1. Company Details

18.4.2. Company Overview

18.4.3. Product Offerings

18.4.4. Key Developments

18.4.5. Financial Analysis

18.4.6. SWOT Analysis

18.4.7. Business Strategies

18.5. Boehringer Ingelheim International GmbH

18.5.1. Company Details

18.5.2. Company Overview

18.5.3. Product Offerings

18.5.4. Key Developments

18.5.5. Financial Analysis

18.5.6. SWOT Analysis

18.5.7. Business Strategies

18.6. CanFel Therapeutics

18.6.1. Company Details

18.6.2. Company Overview

18.6.3. Product Offerings

18.6.4. Key Developments

18.6.5. Financial Analysis

18.6.6. SWOT Analysis

18.6.7. Business Strategies

18.7. ELIAS Animal Health

18.7.1. Company Details

18.7.2. Company Overview

18.7.3. Product Offerings

18.7.4. Key Developments

18.7.5. Financial Analysis

18.7.6. SWOT Analysis

18.7.7. Business Strategies

18.8. Fetch Pharma

18.8.1. Company Details

18.8.2. Company Overview

18.8.3. Product Offerings

18.8.4. Key Developments

18.8.5. Financial Analysis

18.8.6. SWOT Analysis

18.8.7. Business Strategies

18.9. Genentech

18.9.1. Company Details

18.9.2. Company Overview

18.9.3. Product Offerings

18.9.4. Key Developments

18.9.5. Financial Analysis

18.9.6. SWOT Analysis

18.9.7. Business Strategies

18.10. Innogenics

18.10.1. Company Details

18.10.2. Company Overview

18.10.3. Product Offerings

18.10.4. Key Developments

18.10.5. Financial Analysis

18.10.6. SWOT Analysis

18.10.7. Business Strategies

18.11. Karyopharm Therapeutics

18.11.1. Company Details

18.11.2. Company Overview

18.11.3. Product Offerings

18.11.4. Key Developments

18.11.5. Financial Analysis

18.11.6. SWOT Analysis

18.11.7. Business Strategies

18.12. Kindred Biosciences

18.12.1. Company Details

18.12.2. Company Overview

18.12.3. Product Offerings

18.12.4. Key Developments

18.12.5. Financial Analysis

18.12.6. SWOT Analysis

18.12.7. Business Strategies

18.13. Morphogenesis, Inc.

18.13.1. Company Details

18.13.2. Company Overview

18.13.3. Product Offerings

18.13.4. Key Developments

18.13.5. Financial Analysis

18.13.6. SWOT Analysis

18.13.7. Business Strategies

18.14. NIPPON ZENYAKU KOGYO CO., LTD.

18.14.1. Company Details

18.14.2. Company Overview

18.14.3. Product Offerings

18.14.4. Key Developments

18.14.5. Financial Analysis

18.14.6. SWOT Analysis

18.14.7. Business Strategies

18.15. Oasmia Pharmaceutical AB

18.15.1. Company Details

18.15.2. Company Overview

18.15.3. Product Offerings

18.15.4. Key Developments

18.15.5. Financial Analysis

18.15.6. SWOT Analysis

18.15.7. Business Strategies

18.16. PetLife Pharmaceuticals, Inc.

18.16.1. Company Details

18.16.2. Company Overview

18.16.3. Product Offerings

18.16.4. Key Developments

18.16.5. Financial Analysis

18.16.6. SWOT Analysis

18.16.7. Business Strategies

18.17. Pharmaust.

18.17.1. Company Details

18.17.2. Company Overview

18.17.3. Product Offerings

18.17.4. Key Developments

18.17.5. Financial Analysis

18.17.6. SWOT Analysis

18.17.7. Business Strategies

18.18. Phibro Animal Health Corporation

18.18.1. Company Details

18.18.2. Company Overview

18.18.3. Product Offerings

18.18.4. Key Developments

18.18.5. Financial Analysis

18.18.6. SWOT Analysis

18.18.7. Business Strategies

18.19. Regeneus Ltd

18.19.1. Company Details

18.19.2. Company Overview

18.19.3. Product Offerings

18.19.4. Key Developments

18.19.5. Financial Analysis

18.19.6. SWOT Analysis

18.19.7. Business Strategies

18.20. Rhizen Pharmaceuticals S.A.

18.20.1. Company Details

18.20.2. Company Overview

18.20.3. Product Offerings

18.20.4. Key Developments

18.20.5. Financial Analysis

18.20.6. SWOT Analysis

18.20.7. Business Strategies

18.21. Torigen Pharmaceutical Inc.

18.21.1. Company Details

18.21.2. Company Overview

18.21.3. Product Offerings

18.21.4. Key Developments

18.21.5. Financial Analysis

18.21.6. SWOT Analysis

18.21.7. Business Strategies

18.22. Vaccibody

18.22.1. Company Details

18.22.2. Company Overview

18.22.3. Product Offerings

18.22.4. Key Developments

18.22.5. Financial Analysis

18.22.6. SWOT Analysis

18.22.7. Business Strategies

18.23. VetDC

18.23.1. Company Details

18.23.2. Company Overview

18.23.3. Product Offerings

18.23.4. Key Developments

18.23.5. Financial Analysis

18.23.6. SWOT Analysis

18.23.7. Business Strategies

18.24. Virbac.

18.24.1. Company Details

18.24.2. Company Overview

18.24.3. Product Offerings

18.24.4. Key Developments

18.24.5. Financial Analysis

18.24.6. SWOT Analysis

18.24.7. Business Strategies

18.25. Zoetis Services LLC

18.25.1. Company Details

18.25.2. Company Overview

18.25.3. Product Offerings

18.25.4. Key Developments

18.25.5. Financial Analysis

18.25.6. SWOT Analysis

18.25.7. Business Strategies

19. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.